Nonprofit biotech research institute Access to Advanced Health Institute (AAHI) said that it has received an award worth up to $9.9 million for a 40-month project aimed at development of liquid and dry powder versions of an intranasal influenza RNA vaccine candidate targeting the A(H5N1) and A(H7N9) avian influenza subtypes. The funding, which will support … [Read more...] about Access to Advanced Health Institute gets award worth up to $9.9 million for development of intranasal RNA flu vaccine
Business
PTAB again supports Liquidia, denies United Therapeutics rehearing request for Tyvaso patent
According to Liquidia, the US Patent Trial and Appeal Board (PTAB) has denied a request by United Therapeutics to revisit the board's July 2022 determination that none of the claims in US Patent No. 10,716,793, covering Tyvaso inhaled treprostinil, are patentable. Liquidia said that it expects United Therapeutics to appeal the denial of the rehearing to the US Court … [Read more...] about PTAB again supports Liquidia, denies United Therapeutics rehearing request for Tyvaso patent
Optinose names Ramy Mahmoud as CEO
Intranasal drug developer Optinose has announced the appointment of Ramy Mahmoud as CEO, succeeding Peter Miller. Mahmoud has served as Optinose's President and Chief Operating Officer since 2010; before joining the company, he served in a number of roles at Johnson & Johnson, including Chief Medical Officer. The company also announced that it expects to submit … [Read more...] about Optinose names Ramy Mahmoud as CEO
Bharat Biotech launches iNCOVACC intranasal COVID-19 vaccine in India
Bharat Biotech has announced the launch of its iNCOVACC (BBV154) intranasal COVID vaccine in India for use as both primary series and booster. In September 2022, India's Central Drugs Standard Control Organization (CDSCO) approved the use of iNCOVACC in adults aged 18 and older. iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine that Bharat … [Read more...] about Bharat Biotech launches iNCOVACC intranasal COVID-19 vaccine in India
Medical Developments International discontinues planned clinical trials of Penthrox methoxyflurane inhaler in China
Medical Developments International (MVP) said that the company in no longer planning to conduct clinical trials of its Penthrox methoxyflurane inhaler in China due to "extended delays to the anticipated timeline for clinical trial outcomes and consequently the commercial launch of Penthrox in the market, primarily due to the challenging regulatory environment and … [Read more...] about Medical Developments International discontinues planned clinical trials of Penthrox methoxyflurane inhaler in China
Adherium gets almost £500,000 from SBRI Healthcare for inhaler monitoring project
Adherium announced that it received an award of £499,871 for an inhaler monitoring project from Small Business Research Initiative (SBRI) Healthcare, a program from the UK's National Health Service. The project, titled "Smart Digital inhaler enabled asthma management in high-risk children aged 5 to 16 years managed in primary care to prevent asthma attacks," will … [Read more...] about Adherium gets almost £500,000 from SBRI Healthcare for inhaler monitoring project
Isterian Biotech to develop inhaled TG2 inhibitor for the treatment of IPF
Cambrian BioPharma announced that it has partnered with Aston University and Aston Professor Martin Griffin since 2019 on a startup called Isterian Biotech. According to the announcement, the company's pipeline features a transglutaminase 2 (TG2) inhibitor that has been shown to reduce lung fibrosis in a mouse model and which Isterian intends to develop as an inhaled … [Read more...] about Isterian Biotech to develop inhaled TG2 inhibitor for the treatment of IPF
Liquidia announces financing agreement for up to $100 million
Liquidia Corporation said that an investment by HealthCare Royalty (HCRx) of up to $100 million will support further clinical development and the potential launch of the company's Yutrepia treprostinil DPI. In return, HCRx will get tiered royalties on potential net revenue from Yutrepia and other Liquidia products in addition to fixed payments from Liquidia, with … [Read more...] about Liquidia announces financing agreement for up to $100 million
ENA Respiratory gets $4.38 million from US Department of Defense for development of dry powder intranasal formulation of INNA-051
The US Department of Defense Chemical and Biological Defense Program (CBDP) has awarded Australian pharma company ENA Respiratory $4.38 million for development of a dry powder formulation of the company's INNA-051 intranasal pegylated TLR2/6 agonist for protection against a wide range of respiratory viruses, ENA said. According to ENA, the 12-month project is expected … [Read more...] about ENA Respiratory gets $4.38 million from US Department of Defense for development of dry powder intranasal formulation of INNA-051
Lupin launches Difizma triple combination DPI in India
Lupin announced that it has launched its Difizma indacaterol / glycopyrronium / mometasone DPI in India for the treatment of inadequately controlled asthma. The company says that Difizma is the first fixed dose combination approved for the treatment of poorly controlled asthma by the Drug Controller General of India (DCGI). In 2022, Glenmark launched an indacaterol … [Read more...] about Lupin launches Difizma triple combination DPI in India